128 related articles for article (PubMed ID: 28461641)
1. Healthcare Use and Direct Cost of Giant Cell Arteritis: A Population-based Study.
Koster MJ; Achenbach SJ; Crowson CS; Maradit-Kremers H; Matteson EL; Warrington KJ
J Rheumatol; 2017 Jul; 44(7):1044-1050. PubMed ID: 28461641
[TBL] [Abstract][Full Text] [Related]
2. Incremental Costs in Giant Cell Arteritis.
Mounié M; Costa N; Sailler L; Lapeyre-Mestre M; Bourrel R; Savy N; Molinier L; Pugnet G
Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1074-1081. PubMed ID: 28973818
[TBL] [Abstract][Full Text] [Related]
3. Data linkage analysis of giant cell arteritis in Italy: Healthcare burden and cost of illness in the Italian region of Friuli Venezia Giulia (2001-2017).
Valent F; Bond M; Cavallaro E; Treppo E; Rosalia Maria DR; Tullio A; Dejaco C; De Vita S; Quartuccio L
Vasc Med; 2020 Apr; 25(2):150-156. PubMed ID: 31804152
[TBL] [Abstract][Full Text] [Related]
4. Hospitalization rates and utilization among patients with giant cell arteritis: A population-based study from 1987 to 2012.
Michet CJ; Achenbach SJ; Crowson CS; Matteson EL
Semin Arthritis Rheum; 2015 Aug; 45(1):70-4. PubMed ID: 25824865
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population-based retrospective cohort study.
Udayakumar PD; Chandran AK; Crowson CS; Warrington KJ; Matteson EL
Arthritis Care Res (Hoboken); 2015 Mar; 67(3):396-402. PubMed ID: 25074472
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis.
Chen JJ; Leavitt JA; Fang C; Crowson CS; Matteson EL; Warrington KJ
Ophthalmology; 2016 Sep; 123(9):1999-2003. PubMed ID: 27297405
[TBL] [Abstract][Full Text] [Related]
7. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period.
Salvarani C; Crowson CS; O'Fallon WM; Hunder GG; Gabriel SE
Arthritis Rheum; 2004 Apr; 51(2):264-8. PubMed ID: 15077270
[TBL] [Abstract][Full Text] [Related]
8. The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950-2009.
Chandran AK; Udayakumar PD; Crowson CS; Warrington KJ; Matteson EL
Scand J Rheumatol; 2015 May; 44(3):215-8. PubMed ID: 25606666
[TBL] [Abstract][Full Text] [Related]
9. Incidence of giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study.
Brekke LK; Diamantopoulos AP; Fevang BT; Aβmus J; Esperø E; Gjesdal CG
Arthritis Res Ther; 2017 Dec; 19(1):278. PubMed ID: 29246164
[TBL] [Abstract][Full Text] [Related]
10. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015.
Crowson CS; Matteson EL
Semin Arthritis Rheum; 2017 Oct; 47(2):253-256. PubMed ID: 28551169
[TBL] [Abstract][Full Text] [Related]
11. Venous Thromboembolism and Cerebrovascular Events in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study.
Lo Gullo A; Koster MJ; Crowson CS; Makol A; Ytterberg SR; Saitta A; Salvarani C; Matteson EL; Warrington KJ
PLoS One; 2016; 11(2):e0149579. PubMed ID: 26901431
[TBL] [Abstract][Full Text] [Related]
12. Phase-Specific Healthcare Costs Associated With Giant Cell Arteritis in Ontario, Canada.
Junek M; Barra L; Kopp A; Felfeli T; Gatley J; Widdifield J
J Rheumatol; 2024 May; ():. PubMed ID: 38561188
[TBL] [Abstract][Full Text] [Related]
13. Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years.
Elfishawi MM; Kaymakci MS; J Achenbach S; S Crowson C; Kermani TA; M Weyand C; J Koster M; Warrington KJ
RMD Open; 2024 Feb; 10(1):. PubMed ID: 38331471
[TBL] [Abstract][Full Text] [Related]
14. Projected worldwide disease burden from giant cell arteritis by 2050.
De Smit E; Palmer AJ; Hewitt AW
J Rheumatol; 2015 Jan; 42(1):119-25. PubMed ID: 25362658
[TBL] [Abstract][Full Text] [Related]
15. Burden, Causes, and Outcomes of Hospitalization in Patients With Giant Cell Arteritis: A US National Cohort Study.
Goulabchand R; Qian AS; Nguyen NH; Singh AG; Roubille C; Parreau S; Singh N; Singh S
Arthritis Care Res (Hoboken); 2023 Aug; 75(8):1830-1837. PubMed ID: 36576029
[TBL] [Abstract][Full Text] [Related]
16. Lower Frequency of Comorbidities Prior to Onset of Giant Cell Arteritis: A Population-Based Study.
Elfishawi M; Rakholiya J; Gunderson TM; Achenbach SJ; Crowson CS; Matteson EL; Turesson C; Wadström K; Weyand C; Koster MJ; Warrington KJ
J Rheumatol; 2023 Apr; 50(4):526-531. PubMed ID: 36521923
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Severe Infections and Infection-Related Mortality During the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double-Cohort Study.
Schmidt J; Smail A; Roche B; Gay P; Salle V; Pellet H; Duhaut P
Arthritis Rheumatol; 2016 Jun; 68(6):1477-82. PubMed ID: 26815885
[TBL] [Abstract][Full Text] [Related]
18. Direct medical costs of polymyalgia rheumatica.
Kremers HM; Reinalda MS; Crowson CS; Zinsmeister AR; Hunder GG; Gabriel SE
Arthritis Rheum; 2005 Aug; 53(4):578-84. PubMed ID: 16082650
[TBL] [Abstract][Full Text] [Related]
19. Malignancy risk in patients with giant cell arteritis: a population-based cohort study.
Kermani TA; Schäfer VS; Crowson CS; Hunder GG; Gabriel SE; Ytterberg SR; Matteson EL; Warrington KJ
Arthritis Care Res (Hoboken); 2010 Feb; 62(2):149-54. PubMed ID: 20191512
[TBL] [Abstract][Full Text] [Related]
20. Trajectory of Healthcare Resource Utilization in Giant Cell Arteritis: A Population-based Study.
Mohammad AJ; Turkiewicz A; Stamatis P; Turesson C; Englund M; Kiadaliri A
J Rheumatol; 2021 Aug; 48(8):1307-1313. PubMed ID: 33649063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
